Pulmonary hypertension in connective tissue diseases: an update
Authors:
- 1 January 2017
- journal article
- review article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 20 (1) , 5-24
Abstract
Pulmonary hypertension (PH) is a relatively commoner complication of systemic sclerosis (SSc) with estimated prevalence ranging between 8% and 12% as compared to much lower figures in other connective tissue diseases (CTD). It is a major cause of morbidity and mortality in CTDs. PH is classified into five major groups. CTD-associated PH belongs to group 1 PH, also known as pulmonary arterial hypertension (PAH). Around 30% of scleroderma-related deaths are due to PAH. Underlying pathogenesis is related to pulmonary vasculopathy involving small vessels. The Evidence-based Detection of Pulmonary Arterial Hypertension in Systemic sclerosis (DETECT) algorithm outperforms the current European Society of Cardiology/European Respiratory Society guidelines as a screening tool in SSc-PAH; it can, therefore, suggest when to refer a patient for right heart catheterization. CTD-PAH patients constitute at least 20% of patients included in all major trials of PH-specific therapy and the results are comparable to those of idiopathic PAH. The role of anticoagulation in CTD-PAH is associated with a high risk-benefit ratio with the caveat of its potential role in those with severe disease. There appears to be no role of immunosuppression in scleroderma-PAH; however, immunosuppressive agents, namely the combination of glucocorticoids and pulse cyclophosphamide / possibly mycophenolate, may result in clinical improvement in a subset of patients with systemic lupus erythematosus and mixed connective tissue disease-related PAH.Keywords
This publication has 83 references indexed in Scilit:
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionNew England Journal of Medicine, 2013
- Survival and Predictors of Mortality in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma RegistryArthritis Care & Research, 2013
- Survival and Prognostic Factors in Systemic Sclerosis–Associated Pulmonary Hypertension: A Systematic Review and Meta‐AnalysisArthritis & Rheumatism, 2013
- Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort studyArthritis Research & Therapy, 2012
- Pulmonary hypertension in systemic lupus erythematosus: a systematic review and analysis of 642 cases in Chinese populationRheumatology International, 2012
- Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and dilutedDrug Design, Development and Therapy, 2012
- Telangiectases in Scleroderma: A Potential Clinical Marker of Pulmonary Arterial HypertensionThe Journal of Rheumatology, 2009
- Accuracy of Doppler Echocardiography in the Hemodynamic Assessment of Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Changes in causes of death in systemic sclerosis, 1972–2002Annals of the Rheumatic Diseases, 2007
- Cardiovascular manifestations of mixed connective tissue disease in adults.Circulation, 1983